Último número

Volumen 69 (09)
Ver número actual
Ver todos

Números anteriores

Vol. 69 (08)
Vol. 69 (07)
Vol. 69 (06)
Vol. 69 (05)

Otros números

Suplementos Congresos English Versions

Sobre la Revista

Comité Científico Viguera Editores Proceso de revisión Sociedades oficiales e indexación

Información para autores

Enviar manuscrito Normas de publicación Consultar estado de artículo

Información para revisores

Recomendaciones para revisor
Factor Impacto 20180,485

Porcentaje de aceptación en 2018: 36%

En 2018 el 50% de artículos recibieron respuesta definitiva en <=10 días

Media de tiempo a respuesta definitiva en 2018: 32 días

Web Médica Acreditada. Ver más información

Revista de Neurología (24 números al año) fomenta y difunde el conocimiento generado en lengua española sobre neurociencia, tanto clínica como experimental.

Másteres online

Master in Neuroimmunology

Máster en Neurociencia Experimental y Clínica

Máster en Sueño: Fisiología y Medicina

Máster en Neurología Tropical y Enfermedades Infecciosas

Máster en Epilepsia

Máster en Trastornos del Espectro Autista

Máster en Trastornos del Movimiento

Máster en Psicobiología y Neurociencia Cognitiva

Máster en Neuropsicología de las Altas Capacidades Intelectuales

Universidades

iNeurocampus Formación online

Listado de Másteres impartidos por Viguera Editores S.L.U. a través del portal www.ineurocampus.com en colaboración con distintas universidades del país

Noticias del día

Mejorar el nivel de autoconciencia aumenta la independencia funcional de pacientes con daño cerebral adquirido Fecha 15/11/2019 ● Lecturas 7
Ver todas las noticias

 

Logran predecir las áreas cerebrales a estimular para forzar la transición de un estado cerebral a otro Fecha 15/11/2019 ● Lecturas 3

Entrevistas

Entrevista con el profesor Luis de Lecea con ocasión de la reunión de la Asociación Española de Narcolepsia para pacientes y médicos (Día Europeo de la Narcolepsia. Madrid, 2019)

12/03/2019 ● Lecturas 8.573
Ver todas las entrevistas

Listado de noticias de interés relacionadas con las neurociencias

Noviembre 18 2019

XLIII Reunión Anual de la Academia Mexicana de Neurología

Puerto Vallarta, Jalisco, México

Noviembre 19 2019

56ª Congreso Argentino de Neurología

Buenos Aires, Argentina

Noviembre 19 2019

LXXI Reunión Anual de la SEN

Sevilla, España

Noviembre 20 2019

68th Annual Meeting American Society of Tropical Medicina and Hygiene

National Harbor, Maryland, EEUU

Noviembre 20 2019

XXVI Congreso Anual de la Sociedad Española de Enfermería Neurológica y II Congreso Internacional...

Sevilla, España

Noviembre 21 2019

9th World Congress of Neuroendoscopy - IFNE 2019

Orlando, Florida, EEUU

Ver Agenda

Listado de eventos del sector y fechas de interés relacionadas con los Másteres de www.ineurocampus.com

Listado de palabras clave de la página web. Pulse en una categoría para acceder a la búsqueda de todo el contenido web (artículos, noticias, autores, entrevistas etc.) relacionado con dicha categoría

Sobre Revista de Neurología

Información Comité Científico Proceso de revisión Sociedades e indexación Contacto

¿Cómo publicar con nosotros?

Enviar manuscrito Normas para autores Información para revisores

Sobre Viguera Editores

Información

Sobre iNeurocampus

Información

Redes sociales

Facebook Twitter
Web Médica Acreditada. Ver más información

Neurologia.com es una comunidad de conocimiento alrededor de la neurología en habla hispana, compuesta por millones de profesionales, desde estudiantes a instituciones médicas o académicas. Esta comunidad se dota de diferentes herramientas de interrelación y difusión del conocimiento en neurociencia

Entrevista

English Castellano

Interview with Prof. Mehdi Tafti for European Narcolepsy Day 2011

18/03/2011 ● Lecturas 46.410


Dr. Mehdi Tafti Center for Integrative Genomics (CIG), University of Lausanne and Center for Investigation and Research on Sleep (CIRS), Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Question. We know that narcolepsy is a chronic disabling sleep disorder affecting 1 out of every 2000 individuals, but what exactly is the impact of narcolepsy in the European population?
Answer. Narcolepsy is largely underdiagnosed and its prevalence might be much higher. The delay in diagnosis is around 10 years, leaving many patients without adequate treatment for years. This has a huge impact in terms of its socioeconomic, health and welfare burden.

Q. It has been proved that narcolepsy is related to a severe hypocretin-1 deficiency (De Lecea, 1998), and since hypocretin has been reported to be undetectable in the cerebrospinal fluid (CSF) of most narcoleptic patients with cataplexy, is there any autoimmune mechanism explaining the destruction of the hypocretin neurons in the lateral hypothalamus?
A. The cause of hypocretin deficiency is unknown but the most plausible explanation is the destruction of hypocretin neurons. Since narcolepsy is strongly associated with specific HLA (Human Leukocyte Antigen) genes regulating the immune system, an autoimmune process targeting hypocretin neurons might be involved. We have shown that narcolepsy patients are positive for anti-Trib2 (Tribbles Homolog 2) antibodies and these antibodies recognise hypocretin neurons. Nevertheless, half of all narcolepsy patients are negative for these antibodies, leaving the question open. Moreover, both we and others have reported a remarkable positive response to IVIg, a typical anti-autoimmune treatment. Taken together the available data strongly suggest that the cause of narcolepsy might be autoimmune.

Q. We know that the majority of cases of narcolepsy are sporadic, 1-10% of cases are familiar and studies with twins show that only 25-31% of monozygotic twins are concordant for the disease. So, what is the role played by genetic and environmental factors?
A. Narcolepsy is a complex disease and like other complex disorders it is influenced by both genetic and environmental factors. The more we learn about the genetic factors, the more the environmental triggers become important. Unfortunately we know little about the environmental factors, although significant life events such as infections or stressful experiences have been reported as relevant. We are beginning to learn more and more about genetic factors, and this will help us to understand the genetic background that predisposes people to narcolepsy. The high rate of discrepancy between monozygotic twins strongly suggests a critical role for an as-yet unknown environmental factor acting on a genetic predisposition to the disease.

Q. We know that symptoms develop gradually. Cataplexy is often the second symptom to occur, although it appears years after the onset of sleep attacks and some cases remain undetected and misdiagnosed. Do you think that the diagnostic tools currently in use are appropriate?
A. The diagnosis of narcolepsy is a major problem. In up to 80% of the patients excessive daytime sleepiness appears between one and 10 years before cataplexy. Sleepiness without cataplexy is very difficult to investigate and may be related to many conditions other than narcolepsy. Accordingly, most narcolepsy patients either go undiagnosed or misdiagnosed. Moreover, other comorbid disorders such as sleep apnoea, restless legs syndrome, and depression are frequently found in narcolepsy patients, thus making it very difficult to reach a positive diagnosis in the absence of clear-cut cataplexy. An additional problem is the recognition of cataplexy, since no objective test is available and many patients may have partial cataplexy that goes unnoticed. Diagnostic tools are well-established and standardised, but unfortunately not yet completely appropriate.

Q. So far treatment has been symptomatic with stimulants and antidepressants: are there any new perspectives in the pharmacological therapy of narcolepsy?
A. Treatment remains symptomatic because the cause is still unknown. As mentioned before, if narcolepsy is an autoimmune disease, then immunotherapy may be a first choice but it seems that not all cases turn out to be autoimmune in origin. Since hypocretin deficiency is the best biological marker of narcolepsy, hypocretin replacement is the best therapy to date. Unfortunately hypocretins do not cross the blood-brain barrier and there is a strong need to develop centrally-acting hypocretin agonists. Gene- or cell-based therapies are future directions that need intensive research. The existence of several animal models of narcolepsy is highly valuable in the pharmacology management of the condition.

Q. You are a member of the Board of the European Narcolepsy Network (EU-NN), founded in 2007. One of the first results of this European collaboration is the recent paper in Nature Genetics, Hor et al., 2010, which is the first study to identify a genetic protective factor. Could you please summarise the main points of your study?
A. We have known for decades that HLA-DQB1*0602 is strongly associated with narcolepsy but the gene is normal and found in 10-20% of the general population. Therefore the conclusion was that this gene is not sufficient. By comparing European narcolepsy patients with controls matched for this HLA allele, we have found that another HLA allele, present in 10% of controls, is extremely rarely found in patients. This new allele (DQB1*0603) increases the protection against narcolepsy 50 fold in subjects carrying one copy of the susceptibility allele (DQB1*0602). Given that the two proteins produced by these two alleles differ by only two amino acids, our finding strongly suggests that DQB1 is causally involved in narcolepsy. In other words, if DQB1*0602 is found in up to 20% of subjects who are not affected with narcolepsy, one major explanation is that they are protected with another HLA variant.

Q. You are a Professor of the on-line Master Sleep: Medicine and Physiology, which is now in its fifth edition, with a chapter entitled Genetics of Sleep. What are the actual goals of the research in this topic? We know that your team is doing translational research, so could you please give us an overview of your work?
A. This is a vast question. Until now the molecular genetics of sleep have attracted very little interest. My laboratory is tracking down genes that regulate both normal and disordered sleep. We have already identified several important genes that causally affect the sleep EEG in mice, as well as genes associated with narcolepsy, sleepwalking and Kleine-Levin syndrome. More recently we have initiated a large study that looks at sleep and sleep disorders in the general population. The project, called HypnoLaus, is part of a larger cohort study of the Lausanne general population (CoLaus), where 6600 subjects are investigated for hundreds of metabolic, cardiovascular and neuropsychiatric variables. Additionally, all these subjects have been genotyped with over 500,000 genetic markers. The aim of our study is to record sleep in up to 3000 members of this cohort in order to identify genes involved in both normal and pathological sleep. So far nearly 800 subjects have been investigated.
Dr. Rosa Peraita-Adrados
Unidad de Sueño-Neurofisiología Clínica. Hospital Universitario Gregorio Marañón.

Prof. Juan-Vicente Sánchez-Andrés
Director asociado de Revista de Neurología
Departamento médico, Viguera eds.
Sueño
Le puede interesar
Artículo en Castellano
Calidad subjetiva de sueño y análisis espectral del electroencefalograma de sueño nocturno J.M. Vergara-Ugarriza, J. Brualla, M. Serrano, J. Arcocha, F.J. López-Lorente Fecha de publicación 16/04/1999 ● Descargas 380
Artículo en Castellano
Gustavo Pittaluga y la expedición para el estudio de la enfermedad del sueño en los territorios españoles del golfo de Gu... I. Corral-Corral, C. Quereda Rodríguez-Navarro Fecha de publicación 01/01/2012 ● Descargas 307